Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice

Summary

Ectopic delivery of factor VIII (FVIII) to megakaryocytes (Mk) represents a viable approach for localized tenase generation by concentrating the FVIIIa/FIXa enzymecofactor complex onto activated platelet membranes. We utilized a core rat platelet factor 4 (PF4) promoter for Mk/platelet-restricted expression of human B-domain-deleted (hBDD) FVIII within the background of a haemophilia A mouse (rPF4/hBDD/FVIII^-/-). Platelets from rPF4/hBDD/FVIII^-/- mice contained ∼122 mU FVIII:C/1x10⁹ platelets/ml with no detectable plasmatic FVIII:C,and with no effect on α-granule-derived platelet factorV/Va function.Paired tenase assays (± thrombin) confirmed that platelet (pt) FVIII (unlike platelet FV) required thrombin cleavage for complete activation. rPF4/hBDD/FVIII^-/- mice exposed to a thrombocytotic stimulus (thrombopoietin, TPO) demonstrated a statistically-significant 66% reduction in molar ptFVIII activity with a non-significant reduction in total ptFVIII biomass. Decreased molar ptFVIII concentration correlated with loss of phenotypic correction as evaluated using a haemostatic tail-snip assay. Comparative studies using a transgenic mouse expressing human amyloid-β-precursor protein (hAβPP) from the rPF4 promoter confirmed diminished hAβPP expression without affecting endogenous α-granule PF4, establishing generalizability of these observations.While Mk/plateletreleased ptFVIII (unlike pFV) is proteolytically inactive, we also conclude that thrombocytotic stimuli negatively affect ptFVIII bioavailability and phenotypic efficacy, results which correlate best with molar ptFVIII concentration, and not systemically available ptFVIII.

Keywords

Animal models - gene targeting - coagulation factors

• References

• 1 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
• 2 Gitschier J. et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
• 3 Toole JJ. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-346.
• 4 Wood WI. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-336.
• 5 Vehar GA. et al. Structure of human factor VIII. Nature 1984; 312: 337-342.
• 6 Eaton D. et al. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochem 1986; 83: 5939-5942.
• 7 Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a het erologous precipitating antibody. Proc Nat Acad Sci USA 1982; 79: 1648-1652.
• 8 Pittman D, Kaufman R. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Nat Acad Sci USA 1988; 85: 2429-2433.
• 9 Bahou WF. et al. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest 1989; 84: 56-61.
• 10 Foster PA. et al. A major factor VIII binding domain resides within the amino-terminal 292 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-8446.
• 11 Foster PA. et al. An immunogenic region within residues Vall670-Glu684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230-5234.
• 12 Kaufman RJ. et al. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Molec Cell Biol 1989; 09: 1233-1242.
• 13 Fay PJ. et al. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
• 14 Fulcher CA. et al. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-489.
• 15 Bihoreau N. et al. Structural and functional characterization of factor VIII-dII, a new recombinant factor VIII lacking most of the B-domain. Biochem J 1991; 277: 23-31.
• 16 Eaton DL. et al. Construction and characterization of an active factor VIII variant lacking the central onethird of the molecule. Biochem 1986; 25: 8344-8347.
• 17 Toole JJ. et al. A large region (95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Nat Acad Sci USA 1986; 83: 5939-5942.
• 18 Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem 1996; 271: 11120-11125.
• 19 Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12.
• 20 Mathur A. et al. Interaction of factor IXa with factorVIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997; 272: 23418-23426.
• 21 van Dieijen G. et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
• 22 Cawthern KM. et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-4592.
• 23 Butenas S. et al. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660-667.
• 24 Yarovoi HV. et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003; 102: 4006-4013.
• 25 Shi Q. et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 1974-1982.
• 26 Wilcox DA. et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost 2003; 01: 2477-2489.
• 27 Jesty J, Bluestein D. Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Analyt Biochem 1999; 272: 64-70.
• 28 Gould WR. et al. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 2004; 279: 2383-2393.
• 29 Bahou WF. et al. A shear-restricted pathway of platelet procoagulant activity is regulated by IQGAP1. J Biol Chem 2004; 279: 22571-22577.
• 30 Camire RM. et al. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92: 3035-3041.
• 31 Nesheim ME. et al. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962.
• 32 Kane WH. et al. Activation of coagulation factor V by a platelet protease. J Clin Invest 1982; 70: 1092-1100.
• 33 Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. Hum Pathol 1987; 18: 162-169.
• 34 Miletich JP. et al. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest 1978; 62: 824-831.
• 35 Borchgrevink CF, Owren PA. The hemostatic effect of normal platelets in hemophilia and factor V deficiency. The importance of clotting factors adsorbed on platelets for normal hemostasis. Acta Med Scand 1961; 170: 375-383.
• 36 Ravid K. et al. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Nat Acad Sci USA 1991; 88: 1521-1525.
• 37 Gnatenko D. et al. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to hemophilia A gene therapy. Br J Haematol 1999; 104: 27-36.
• 38 Xu F. et al. Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Nat Acad Sci USA 2005; 102: 18135-18140.
• 39 Bi L. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-121.
• 40 Schmidt VA. et al. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008; 28: 1489-1502.
• 41 Heid CA. et al. Real time quantitative PCR. Genome Res 1996; 06: 986-994.
• 42 Gnatenko DV. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-2293.
• 43 Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66: 1189-1195.
• 44 Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347.
• 45 Jesty J, Godfrey HP. Parlin, a general microcomputer program for parallel-line analysis of bioassays. Am J Clin Pathol 1986; 85: 485-489.
• 46 Pittman DD. et al. Biochemical, immunological, and in vivo functional characterization of B-domaindeleted factor VIII. Blood 1993; 81: 2925-2935.
• 47 Schmidt VA. et al. IQGAP2 functions as a GTP-dependent effector protein in thrombin-induced platelet cytoskeletal reorganization. Blood 2003; 101: 3021-3028.
• 48 Kufrin D. et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 926-933.
• 49 Yang TL. et al. Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression. Thromb Haemost 2000; 83: 70-77.
• 50 Bucki R. et al. Calcium induces phospholipid redistribution and microvesicle release in human erythrocyte membranes by independent pathways. Biochemistry 1998; 37: 15383-15391.
• 51 Gaffet P. et al. Transverse redistribution of phospholipids during human platelet activation: evidence for a vectorial outflux specific to aminophospholipids. Biochemistry 1995; 34: 6762-6769.
• 52 Gnatenko DV. et al. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus. Thromb Haemost 2004; 92: 317-327.
• 53 Tracy PB. et al. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982; 60: 59-63.
• 54 Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem 1990; 265: 17132-17140.
• 55 Denis MM. et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
• 56 Sun H. et al. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102: 2856-2861.
• 57 Kahr WH. et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-265.
• 58 Pipe SW. et al. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998; 273: 8537-8544.
• 59 Nguyen HG. et al. Conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Blood 2005; 106: 1559-1564.
• 60 Kaluzhny Y. et al. A selective effect of Mpl ligand on mRNA stabilization during megakaryocyte differentiation. FEBS letters 2002; 527: 279-283.